Bazedoxifene
From Wikipedia, the free encyclopedia
 |
|
|
Bazedoxifene
|
|
| Systematic (IUPAC) name | |
| 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]- 2-(4-hydroxyphenyl)-3-methyl-indol-5-ol |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C30H34N2O3 |
| Mol. mass | 470.603 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Bazedoxifene is a selective estrogen receptor modulator (SERM), developed by Wyeth Pharmaceuticals, undergoing clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. It is currently in the early phases of review by the United States' Food and Drug Administration.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
